Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somapacitan Once-Weekly vs Daily Norditropin in Pediatric Growth Hormone Deficiency
2023-506829-11-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised trial of somapacitan in growth hormone deficiency (GHD) (2 arms), sponsored by Novo Nordisk. Started Jun 2024; status: completed.
02
Drugs
somapacitan
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2023-506829-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506829-11-00.